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Abstract
Purpose of Review Microvesicles (MVs) have been
recognised as mediators of stem cell function, enabling and
guiding their regenerative effects.
Recent Findings MVs constitute one unique size class of
extracellular vesicles (EVs) directly shed from the cell
plasma membrane. They facilitate cell-to-cell communi-
cation via intercellular transfer of proteins, mRNA and
microRNA (miRNA). MVs derived from stem cells, or
stem cell regulatory cell types, have proven roles in tissue
regeneration and repair processes. Their role in the main-
tenance of healthy tissue function throughout the life
course and thus in age related health span remains to be
elucidated.
Summary Understanding the biogenesis and mechanisms
of action of MVs may enable the development of cell-free
therapeutics capable of assisting in tissue maintenance and
repair for a variety of age-related degenerative diseases.
This review critically evaluates recent work published in
this area and highlights important new findings demon-
strating the use of MVs in tissue regeneration.
Keywords Microvesicles  extracellular vesicles  Stem
cells  Tissue regeneration  Regenerative medicine 
Ageing
Introduction
A large component of physiological homeostasis has been
attributed to the action of extracellular vesicles (EVs),
which are thought to have a key role in tissue maintenance
and repair. EVs can be defined as all membranous vesicles
that are secreted by cells and that encapsulate bioactive
molecules, including a variety of proteins and nucleic
acids. EVs consist of at least three distinct vesicle groups
characterised by size, shape and point of cellular origin.
These comprise Microvesicles (MVs), exosomes and
apoptotic bodies. MVs vary in size, ranging from 100 to
1000 nm in diameter [1, 2], while exosomes and apoptotic
bodies have a diameter less than 100 nm [1–5]. While MVs
and exosomes are the focus of the majority of biomedical
research, the functions and character of other EVs are less
well understood. EVs can be found in most human bio-
logical fluids and interestingly, have been reported to
contain non-coding RNAs [6–8] and double-stranded DNA
[9]. It has been postulated that EVs provide a means of
intercellular communication both in physiological and
pathological states, by transferring their molecular
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payloads from donor to recipient cells throughout the
human body [8, 10]. This transfer of biologically active
molecules can generate functional changes in the recipient
cells [6] and may also provide a molecular basis for the
spread of allostatic load and the effects of non-cell auton-
omous senescence across the body [11].
A direct sequitur of this hypothesis is that both the
MV class and the exosome class of EVs have been
experimentally shown to significantly assist and improve
the rate of paracrine-mediated tissue damage repair.
Specifically, as part of the repair process, the phenotype
of the recipient cells can be altered by three proposed
mechanisms through interactions with MV-associated
components. Firstly, by translation of the mRNA mole-
cules present in MVs, once endocytosis has taken place
and the mRNAs are located within the recipient cell
cytoplasm. Secondly, by negative regulation of the
recipient cell mRNA molecules by the MV-associated
microRNA (miRNA) regulators. Thirdly, by direct MV-
associated protein activity within the recipient cell.
These will now be discussed with a primary focus on the
contribution of MVs to tissue and organ regeneration and
in comparison to Exosomes.
Microvesicles
MVs were once thought to be cell debris, but recent
research has indicated that they have a proven role in
intercellular communication, stem cell regulation and as
potential therapeutic entities for tissue repair
[10, 12, 13]. They are the product of budding from the
cell membrane and they are shed from almost all cell
types as free spherical vesicles [14]. Consequently, MVs
are found in most biological fluids, such as plasma,
urine, synovial fluid and bronchial lavage fluid [15, 16].
Cells are triggered to generate high quantities of MVs in
response to a variety of stimuli, such as differentiation,
senescence and stress; however, the mechanisms are not
clear [17]. Furthermore, increased intracellular calcium
levels are suggested to enhance MV production, via
phospholipid position changing and flipping of phos-
phatidyl-serine from the inside to the outside of the cell
membrane [15, 17, 18]. Here, it needs to be highlighted
that MVs are different from and should not be confused
with exosomes, which are smaller than MVs in size
(40–100 nm in diameter) [4] and are secreted by cells via
a completely different mechanism that involves fusion of
multivesicular endosomes with the plasma membrane
[15, 19, 20]. MVs must also be distinguished from
apoptotic bodies (1000–4000 nm in diameter) that are
secreted from dying cells during apoptosis [6].
Mode of Action
MVs have been recognized as carriers of protein and
genetic material, such as mRNA, miRNA and other small
non-coding RNAs, that can be secreted from almost all
types of cells and affect the phenotype of recipient cells
[21], either transcriptionally or post-transcriptionally [7].
Interestingly, both MVs and exosomes contain and transfer
a particular set of mRNA and miRNA molecules, some of
which are not present in the cytoplasm of the donor cell,
suggesting that these molecules may have been produced
by the donor cell in order to facilitate intercellular com-
munication and affect the phenotype and processes of
recipient cells [8].
MVs derived from stem cells, or stem cell regulatory
cells, have been consistently shown to play an essential
role in stem cell-mediated repair of tissue damage. While
different types of stem cells have been used in various cell
transplantation therapies, no evidence currently exists to
suggest that any significant number of the adult-derived
stem cells have differentiated and subsequently produced
large populations of organ-specific cells in vivo. Addi-
tionally, it is apparent that the transplantation and subse-
quent action of different stem cell types under specific
tissue damage produces similar outcomes with adminis-
tration of conditioned medium from mesenchymal stem
cells (MSCs) in terms of tissue regeneration [22]. Hence,
these observations, along with findings that demonstrate
the secretion of MV paracrine elements from stem cells and
the presence of MVs in stem cell-conditioned medium,
indicate that stem cells might exert their regenerative
properties through MV-mediated paracrine mechanisms
[22, 23].
Recently, the miRNA signatures for the aforementioned
intercellular communication factors from stem cells and
stem cell regulatory cell types have been investigated as
potential therapeutic agents [24]. Extracellular miRNAs
can be found in MVs in the bloodstream as well as in other
body fluids, and they can be transferred horizontally
between cells [25]. miRNAs typically comprise 22
nucleotide, non-coding RNA molecules that act as negative
regulators of gene expression by suppressing the expres-
sion of genes post-transcriptionally [26]. The donor cell
miRNA molecules bind to complementary sequences in the
coding or 30 untranslated region of the recipient cell
mRNAs and inhibit their translation or promote their
degradation. The donor cell miRNA molecules bind to
complementary sequences in the coding or 30 untranslated
region of the recipient cell mRNAs and inhibit their
translation or promote their degradation. In this way,
miRNAs can silence the translation of mRNA and subse-
quently influence a range of biochemical processes,
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including proliferation, apoptosis and regulation of meta-
bolism. Notably, miRNAs may also function to regulate
cellular differentiation processes and tissue homeostasis.
For instance, terminal differentiation of osteoclasts and
angiogenesis, which is an essential process for organ
growth and repair [27], are regulated by miRNAs [28].
Furthermore, it has been shown that stem cell MVs alone
can promote angiogenesis in vivo in a similar fashion to
stem cell treatment [29]. Moreover, MVs isolated from
embryonic stem cells have been shown to induce repro-
gramming of hematopoietic progenitor cells [30]. Thus,
MVs are excellent candidates for novel therapeutic tools
for tissue regeneration, through angiogenesis, stem cell
differentiation, cell migration and activation of anti-
apoptosis.
Ageing is also believed to be regulated, in part, by
miRNAs, either circulating free or encapsulated in EVs,
such as MVs and exosomes, raising the possibility that age-
related paracrine signalling mechanisms employed by stem
cells may be implicated in processes tightly associated with
age-associated tissue degeneration [26, 31, 32]. Different
expression levels of several miRNAs have been found with
age in a variety of species, from human to worm, where
upregulation of specific miRNAs induces cell senescence
with ageing. Moreover, miRNAs enclosed in MVs and
exosomes have been shown to play a role in a number of
age-related diseases, such as atherosclerosis, osteoporosis,
Alzheimer’s disease and type 2 diabetes mellitus [33].
Consequently, paracrine signalling mechanisms may be
implicated in processes tightly associated with age related
tissue maintenance and damage repair. Consequently, MVs
also have the potential to become a cell-free therapeutic
agent for treating age-related degenerative diseases, as well
as for achieving an increase in healthy lifespan through the
mitigation of the drivers of age-related loss of physiolog-
ical function. This approach also has the important addi-
tional bonus of providing a therapeutic vehicle that avoids
the ethical complications and technical hurdles that are still
associated with stem cell transplantation therapies [34, 35].
However, scientific breakthroughs in this area of research
are essential so as to produce more data and advance our
knowledge in order to make MV therapies a reality.
The above-mentioned observations have added a new
dimension in the research on MVs, stem cells and regen-
erative medicine. Hence, MVs may provide a novel means
for the development of prospective strategies of cell-free
regenerative therapies ultimately aiming to tackle other-
wise intractable pathologies, improve age-related health
span and mitigate the effects of degenerative diseases by
tissue regeneration [36].
The first step towards exemplifying the use of MVs as a
cell-free therapeutic for the treatment of tissue and organ
damage have now begun [24, 37]. One recent
exemplification has been the use of rat MVs to regenerate
damaged pancreata in mice.
Pancreas Recovery and Protection Against Kidney
Damage
Pathfinder cells (PCs) are a putative stem cell regulatory
cell type that has been demonstrated to enable tissue
regeneration in two models of solid organ damage
(kidneys and pancreas), working across both concordant
and discordant xenotransplantation barriers in vivo. PCs
have demonstrated the ability to stimulate regeneration
following acute ischaemic renal damage [38] and to
completely reverse the effects of streptozotocin (SZT)-
induced diabetes in mice [39]. In both instances, the
mode of action of the PCs, independently of the species
of origin, was paracrine in nature, suggesting that PC-
derived MVs and their cargo could play a key role in
regulating organ repair.
A recent study by McGuinness et al. has elegantly
demonstrated that MVs derived from rat PCs could stim-
ulate functional recovery of pancreata in mice with SZT-
induced diabetes, exactly as PCs themselves. In addition,
this study highlighted that only the PC MV class and not
PC exosomes could stimulate functional recovery of the
pancreas in vivo [40•]. This, to the best of our knowledge,
is the first time that a direct functional comparison has been
made between the regenerative capacity of MVs and exo-
somes in an in vivo model. This observation suggests that
MVs from other cell types may also be superior to exo-
somes in enabling tissue regeneration in vivo.
MVs derived from adult human MSCs have also been
demonstrated to be protective against renal damage fol-
lowing glycerol-induced, ischemia–reperfusion and cis-
platin-induced acute kidney injury via horizontal transfer
of mRNA and miRNA molecules [41–43]. Several other
studies have also indicated that MSC MVs can reverse
acute and chronic kidney injury in a variety of experi-
mental models, via inhibition of apoptosis and stimulation
of proliferation [44, 45].
However, MSC exosomes have not been shown to be
capable of assisting tissue regeneration and inducing pos-
itive effects in in vivo models of pancreatic and/or renal
damage. Interestingly though, it is worth highlighting that
MSC exosomes have been previously observed to assist
wound healing in vitro [46]. In other words, it appears that
the regenerative effect of exosomes, either of MSC or PC
origin, is limited to in vitro models as far as pancreas and
kidney damage are concerned. Hence, the factors under-
lying variation in the regenerative efficacy of exosomes
between in vitro and in vivo pancreatic and renal studies
are worth addressing in future research. Thus, it becomes
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apparent that it is vitally important to both explore and
recognise the differences between these two types of EVs.
Understanding the differences between MVs and exosomes
in processes such as biogenesis and interaction with
recipient cells, as well as mode of action, both in vitro and
in vivo, could prove to be vital in devising therapeutic
strategies with highly potential outcomes in the near future.
Finally, endothelial progenitor cells have been used as a
source of MVs with potential therapeutic and protective
properties. These MVs have been shown to protect against
kidney damage following ischemia–reperfusion in rats,
through a mechanism involving miRNA delivery to resi-
dent renal cells [47]. Nevertheless, it is clear that more
studies are needed in order to fully assess the efficacy and
complete mode of action of MVs in pancreas and renal
repair before their translation into human therapies [48].
Cardiac Regeneration
MVs have also been suggested as potential therapeutic
effectors in cardiac regeneration. For the first time, MVs
derived from human-induced pluripotent stem cells (iPSCs)
were shown to transmit proteins and RNAs to cardiac
MSCs in vitro, affecting their transcriptome and proteome
and enhancing their cardiac and endothelial differentiation
potential [49•]. Paracrine factors derived from these iPSCs
were later isolated and used in an in vivo setting in which
mice were exposed to acute myocardial ischemia/reperfu-
sion injury. The results suggested that both the MVs and
exosomes from the iPSCs were able to transfer miRNAs to
the ischemic myocardium and protect the cardiomyocytes
through the inhibition of apoptosis [50]. Moreover, a study
by Feng et al. showed that the MSC paracrine factors are
involved in the protection of ischemic cardiomyocytes by
transmission of a specific miRNA, miR-22, leading to
reduced apoptosis. This observation was validated in MSCs
and neonatal cardiomyocytes co-cultures in vitro, and
in vivo using a myocardial infarction mouse model [51].
While more future in vivo studies are warranted in order to
prove this concept, these findings described above open the
way for the potential development of safe acellular thera-
peutic applications, avoiding the challenges, both ethical
and technical, of pluripotent stem cell transplantation
therapies [35], not only for cardiac regeneration but also
for the repair of other tissues.
Retinal Regeneration
The therapeutic potential of MVs has also been investi-
gated in the context of retinal regeneration. MVs were
isolated from mouse embryonic stem cells, and their
capability to affect Mu¨ller cells (a type of quiescent retinal
glial cell) and alter them into a more permissive state for
regeneration of damaged retina was investigated. It was
subsequently shown that MVs were capable of transferring
mRNAs and miRNAs to cultured Mu¨ller cells, enabling
them to re-enter the cell cycle by induction of pluripotency.
This was then followed by differentiation into cells of
retinal lineage [52•]. The same group has on-going studies
testing the therapeutic effect of MVs in vivo, in mice with
damaged retinas, and the outcomes would be of great
interest for establishing novel applications of MVs in tissue
regeneration.
Treatment of Lung Injury
MSCs have previously been discussed as an attractive
therapeutic approach for the treatment of acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS). In
addition, emphasis has been given to the potential role of
the paracrine factors that these cells secrete [53, 54].
Similarly, MSCs have been used as a therapeutic approach
for combating developmental lung injury and lung vascular
diseases [55]. The significance of paracrine factors in the
treatment of the above disorders was later highlighted
in vitro by restoring sodium transport and preserving
epithelial permeability in an ALI model of rat alveolar
epithelial cells, after addition of MSC-conditioned media,
which included EV paracrine factors, such as MVs and
exosomes [56]. Previously, exosomes derived from bone
marrow MSCs have been shown to provide a protective
effect during hypoxia-induced pulmonary hypertension.
This protective effect was mitigated by suppression of
hyper-proliferative pathways, such as the STAT3-mediated
signalling pathway, induced by hypoxia [57]. More
recently, MVs have been shown to have a significant
therapeutic potential in treating ALI and ARDS in vivo, in
mice that had endotoxin-induced ALI with Escherichia coli
infection. The MVs that were used for this purpose were
derived from human MSCs of bone marrow origin. These
MVs were shown to have a positive therapeutic effect and
mitigate the effects of ALI in mice [58].
Nervous System Repair Therapies
MVs have also been discussed as critical to a variety of
events in the nervous system. Interestingly, they could both
provide protection from neurodegeneration and have a
central role in the propagation of neurotoxicity [59]. Exo-
somes have been implicated in spreading the key disease
molecules of Parkinson’s and Alzheimer’s diseases through
the brain [60], and MVs may also play a part in this
184 Curr Pathobiol Rep (2016) 4:181–187
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important disease process. As far as their protective action
is concerned, MSC-based therapies applied in numerous
models of neurodegenerative disorders have provided
strong evidence of paracrine regeneration effects [61]. Xin
et al. demonstrated that exosome paracrine factors origi-
nating from MSCs can have a positive effect on neural cells
after experimentally induced stroke in rodents, by the
transfer of the miR-133b miRNA [62–64]. More recently,
another group showed both in vitro and in vivo that MVs
isolated from macrophages, which have been highly asso-
ciated with regeneration of peripheral nerves, stimulated
proliferation and migration of Schwann cells [65•]. Sch-
wann cells are cells of the peripheral nervous system that
contribute to axonal regeneration after nerve injury. These
results provide a novel strategy for the development of
nervous system repair therapeutics with the use of either
MVs or exosomes. Nevertheless, the potential of EVs to
transfer toxic molecules, as may occur in nervous system
diseases, should be taken into consideration and thoroughly
investigated, before safe and efficient therapies can be
devised for the repair of nerve damage.
Conclusions
Overall, robust evidence exists to support the premise that
MVs are capable of horizontally transferring proteins,
mRNA and miRNA from donor to recipient cells and
subsequently affecting their phenotype [6, 8, 30]. MVs can
stimulate functional changes in the recipient cells by three
proposed mechanisms; protein action, mRNA translation
and negative post-transcriptional regulation of gene
expression facilitated by miRNA action. These phenotypic
changes conferred by MVs through paracrine mechanisms
allow for stem cell regulation and therapeutic efficacy
during tissue regeneration via anti-apoptosis and enhanced
angiogenesis.
The potential of MVs to develop effective therapeutic
interventions in the near future has been demonstrated
numerous times over the past few years, and their role in
tissue regeneration through the horizontal transfer of
bioactive molecules in intercellular communication has
become widely accepted. Additionally, genetic engineering
may be used to modify MV-producing cells to give rise to
higher quantities of MVs with enhanced tissue regeneration
efficiency in vivo, based on the presence and possibly
quantity of their paracrine effectors, such as miRNAs.
Alternatively, production of synthetic MVs that carry the
required bioactive apparatus necessary to facilitate the
transfer of damage repair signals could be deployed, for the
treatment of tissue impairment in degenerative diseases or
tissue decay that comes with ageing.
MVs are in clinical trials and/or moving into clinical
trials on a number of fronts [66]. However, for safe and
successful clinical applications to be developed, more
research is essential into the field of MVs, so as to fur-
ther understand their biogenesis, transport and biological
mode of action. It is also important to identify all the
bioactive species that are found within MVs and under-
stand how they change depending on the donor cells and
what their exact mechanism of action is once they con-
tact the recipient cells. Moreover, it would be of sig-
nificant interest to understand how the production of
MVs, their interaction with target cells and/or their
payload changes with age. In other words, it is important
that MVs remain therapeutically efficient and safe for
use in tissue regeneration with ageing, as ageing is a
major risk factor for many degenerative diseases, apart
from the tissue decay that is its physiological outcome.
Also, it is worth exploring the possibility that MVs and
other EVs, such as exosomes, act as vehicles for
spreading age-related allostatic load within the body.
Additionally, it is of vital importance to become able to
exploit their regenerative and anti-apoptotic properties
more accurately and efficiently for different organs,
tissues and cell types. In order to do so, it is important to
develop large scale MV production, as well as isolation
and purification methods. Also it is essential that tech-
nologies are developed that are capable of efficiently
separating MVs from apoptotic bodies and investigate
what cell populations and which cargoes are suitable for
devising different therapeutic strategies. Finally, it is
necessary to provide guidance on various important
ethical, technical, legal and regulatory issues that could
potentially arise, concerning the use of MVs as a thera-
peutic intervention for tissue damage, degenerative dis-
eases and ageing.
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